spacer
home > ict > autumn 2017 > on the record
PUBLICATIONS
International Clinical Trials

On the Record

Undoubtedly, precision medicine is gaining momentum.
Recent reports put the market on a growth track to reach
$65-75 billion by 2021, with an estimated average growth
rate of 10-12% (1-3). A flurry of announcements regarding
the main focus therapy area, oncology, shows that the field
is attracting a lot of research attention as well as funding.

Cases in point: the $215 million committed to the
Precision Medicine Initiative database in 2015 and
the subsequent $1.45 billion allocated to precision medicine
as part of the 21st Century Cures Act by the Obama
Administration (4). Meanwhile, China launched a five-year,
$3 billion precision medicine initiative in 2016, and the UK
has announced €300 million funding for a four-year project
to map 100,000 of people’s genomes this year (3,5).
The Swiss pharmaceutical hub of Basel – home to powerhouses
Novartis and Roche – has set up a cross-industry innovation
platform for precision medicine, and Qatar has established a
world-class genome project and biobank (6,7).

This surge of activity has been spurred by innovations
in medical technologies, such as drug discovery, companion
diagnostics, next-generation sequencing, bioinformatics
and big data analytics. These allow the diagnosis of certain
diseases based on the analysis of genetic information –
via genomics and specific biomarker techniques – and
the ability to treat particular diseases with new genetic
manipulation methods.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Clinerion'sTigran Arzumanov, PhD, MBA,
has been working in the area of Clinical
Research Sales and Marketing since
2004 and has extensive experience in
commercial aspects of both pharma
research services and eClinical solutions.

Le Vin Chin
is Head of Marketing
and Communications at Clinerion and
has been working in communications
and marketing for 20 years in a wide
variety of industries, including software
and services.
spacer
Tigran Arzumanov
spacer
spacer
spacer
Le Vin Chin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

York Health Economics Consortium offers a new health utilities training course

Cost-utility analysis is a requirement for NICE health technology appraisals and is being increasingly used in other contexts and countries. Health utilities, a crucial component of cost-utility analysis, capture the relative change in health-related quality of life resulting from a treatment. As such, health utility can be a key driver of the cost-effectiveness ratio. Obtaining health utility values that are suitable for your economic evaluation, however, may not always be straight forward.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 
Industry Events

9th Global Drug Delivery & Formulation Summit

12-14 March 2018, Maritim proArte Hotel Berlin

The DDF Summit brings the most interesting studies and exciting technologies to you. This year there will be 4 dedicated streams focusing on Small Molecules, Biologics, Technology & Innovation and for the first-time Device Development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement